Researchers Gain Detailed Insight into Failing Heart Cells using New Nano-technique
News Feb 25, 2010
Heart failure is a progressive and serious condition in which the heart is unable to supply adequate blood flow to meet the body's needs. Hormones such as adrenaline, which are activated by the body in an attempt to stimulate the weak heart, eventually produce further damage and deterioration. Symptoms include shortness of breath, difficulty in exercising and swollen feet.
In the new study, published today in the journal Science and funded by the Wellcome Trust and the Leducq Foundation, researchers were able to analyse individual regions on the surface of the heart muscle cell in unprecedented detail, using live nanoscale microscopy.
They used a new technique called scanning ion conductance microscopy (SICM), which gives an image of the surface of the cardiac muscle cell at more detailed levels than those possible using conventional live microscopy. This enabled the researchers to see fine structures such as minute tubes (t-tubules), which carry electrical signals deep into the core of the cell. They could also see that the muscle cell surface is badly disrupted in heart failure.
There are two types of receptors for adrenaline. The first, beta1AR, strongly stimulates the heart to contract and it can also induce cell damage in the long term. The second, beta2AR, can slightly stimulate contraction but it also has special protective properties. For today's study, the researchers combined SICM with new chemical probes which give fluorescent signals when beta1AR or beta2AR is activated.
They found that the beta2AR receptors are normally anchored in the t-tubules, but in those cells damaged by heart failure they change location and move into the same space as beta1AR receptors. The researchers believe that this altered distribution of receptors might affect the beta2AR receptors' ability to protect cells, and lead to more rapid degeneration of the failing heart.
One of the most important categories of drugs for slowing the development of heart failure are the beta-blockers, which prevent adrenaline from affecting the heart cells by targeting the beta receptors. The new finding increases understanding of what happens to the two receptors in heart failure and could lead to the design of improved beta-blockers. It may eventually help resolve an existing debate about whether it is better to block the beta2AR receptors as well as the beta1AR.
Dr Julia Gorelik, corresponding author of the study from the National Heart and Lung Institute at Imperial College London, said: "Our new technique means we can get a real insight into how individual cells are disrupted by heart failure. Using our new nanoscale live-cell microscopy we can scan the surface of heart muscle cells to much greater accuracy than has been possible before and to see tiny structures that affect how the cells function.
"Through understanding what's happening on this tiny scale, we can ultimately build up a really detailed picture of what's happening to the heart during heart failure and long term, this should help us to tackle the disease. The main question for our future research will be to understand whether drugs can prevent the beta2-AR from moving in the cell and how this might help us to fight heart failure," added Dr Gorelik.
For the study, the researchers looked at single living cardiac muscle cells in a culture dish, taken from healthy or failing rat hearts. They stimulated the beta1AR and beta2AR receptors using drugs applied via nanopipette inside the t-tubules on the heart muscle cell.
Combating Cancer by Targeting Sugar ReceptorsNews
Globally, cancer is the second leading cause of death, also because the efficiency of chemotherapeutics is inadequate due to poor delivery to the tumor. Prof. Olivia Merkel and her team develop targeted nanocarrier systems to increase the delivery rates of therapeutic formulations and their specific uptake into the target cells.READ MORE
Emergex Awarded Innovate UK Grant to Progress its Universal and Pandemic Flu VaccineNews
Emergex Vaccines Holding Limited, a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, announces that Innovate UK, the UK’s innovation agency, has awarded the company a grant of £979,318 to progress its universal flu vaccine programme through preclinical development.READ MORE
Comments | 0 ADD COMMENT
World Congress on Bio-organic and Medicinal Chemistry
Nov 12 - Nov 13, 2018